Free Trial
NASDAQ:ABEO

Abeona Therapeutics (ABEO) Stock Price, News & Analysis

Abeona Therapeutics logo
$6.41
+0.05 (+0.79%)
(As of 10/31/2024 ET)

About Abeona Therapeutics Stock (NASDAQ:ABEO)

Key Stats

Today's Range
$6.04
$6.43
50-Day Range
$5.12
$6.74
52-Week Range
$3.05
$9.01
Volume
253,506 shs
Average Volume
436,978 shs
Market Capitalization
$262.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00
Consensus Rating
Buy

Company Overview

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Abeona Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
69th Percentile Overall Score

ABEO MarketRank™: 

Abeona Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 368th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Abeona Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Abeona Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Abeona Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Abeona Therapeutics are expected to decrease in the coming year, from ($1.28) to ($1.39) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Abeona Therapeutics is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Abeona Therapeutics is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Abeona Therapeutics has a P/B Ratio of 10.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Abeona Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    7.07% of the float of Abeona Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Abeona Therapeutics has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Abeona Therapeutics has recently increased by 3.75%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Abeona Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Abeona Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.07% of the float of Abeona Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Abeona Therapeutics has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Abeona Therapeutics has recently increased by 3.75%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Abeona Therapeutics has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Abeona Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    Only 7 people have searched for ABEO on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Abeona Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Abeona Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.30% of the stock of Abeona Therapeutics is held by insiders.

  • Percentage Held by Institutions

    80.56% of the stock of Abeona Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Abeona Therapeutics' insider trading history.
Receive ABEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ABEO Stock News Headlines

Abeona Therapeutics completes Pz-cel BLA resubmission to U.S. FDA
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Rosalind Advisors, Inc. Expands Stake in Myomo Inc
See More Headlines

ABEO Stock Analysis - Frequently Asked Questions

Abeona Therapeutics' stock was trading at $5.01 at the beginning of the year. Since then, ABEO shares have increased by 27.9% and is now trading at $6.41.
View the best growth stocks for 2024 here
.

Abeona Therapeutics Inc (NASDAQ:ABEO) announced its quarterly earnings data on Monday, August, 12th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by $0.42.

Abeona Therapeutics's stock reverse split on the morning of Tuesday, July 5th 2022. The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Top institutional investors of Abeona Therapeutics include Rosalind Advisors Inc. (4.47%) and abrdn plc (0.80%). Insiders that own company stock include Vishwas Seshadri, Brendan M O'malley, Michael Amoroso, Christine Berni Silverstein, Faith L Charles and Mark Alvino.
View institutional ownership trends
.

Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Abeona Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), CymaBay Therapeutics (CBAY) and General Electric (GE).

Company Calendar

Last Earnings
8/12/2024
Today
10/31/2024
Next Earnings (Estimated)
11/11/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ABEO
Previous Symbol
OTCMKTS:ACCP
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.00
High Stock Price Target
$21.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+190.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-54,190,000.00
Pretax Margin
-2,190.26%

Debt

Sales & Book Value

Annual Sales
$3.50 million
Book Value
$0.60 per share

Miscellaneous

Free Float
41,018,000
Market Cap
$253.97 million
Optionable
Optionable
Beta
1.53
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ABEO) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners